Skip to content
Back to ORIC

Oric Pharmaceuticals, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
16
Purchases
0
Sales
16
Purchase value
$0.00
Sale value
$2.96M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Dominic PiscitelliChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Oct 21, 2026Period of report Oct 20, 20260001695028-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 20, 2026
Common StockF1F214,000$13.5279$189.39K69,828Direct
Filing footnotes · 2
  1. F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
  2. F2Represents the weighted average share price of an aggregate total of 14,000 shares sold in the price range of $13.50 to $13.65 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Richard A. HeymanDirector
4Rule 10b5-1 plan disclosed
Filed Oct 2, 2026Period of report Oct 1, 20260001584759-26-000017
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleOct 1, 2026
Common StockF1F23,500$12.9141$45.20K38,300Direct
SaleOct 1, 2026
Common StockF1F2F33,200$12.9141$41.33K203,472IndirectSee footnote
Filing footnotes · 4
  1. F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  2. F2This transaction was executed in multiple trades at prices ranging from $12.57 to $13.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. F3The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
  4. F4The shares subject to the option are fully vested and immediately exercisable.
Open on SEC EDGAR
Dominic PiscitelliChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Sep 29, 2026Period of report Sep 28, 20260001695028-26-000010
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 28, 2026
Common StockF1F213,400$13.5267$181.26K69,828Direct
Filing footnotes · 2
  1. F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
  2. F2Represents the weighted average share price of an aggregate total of 13,400 shares sold in the price range of $13.50 to $13.575 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Dominic PiscitelliChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Sep 25, 2026Period of report Sep 24, 20260001695028-26-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleSep 24, 2026
Common StockF1100$13.50$1.35K70,328Direct
SaleSep 24, 2026
Common StockF1500$13.505$6.75K69,828Direct
Filing footnotes · 1
  1. F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
Open on SEC EDGAR
Dominic PiscitelliChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Aug 28, 2026Period of report Aug 26, 20260001695028-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 26, 2026
Common StockF277,000$13.6859$1.05M69,828Direct
Filing footnotes · 3
  1. F1Includes 1,680 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
  2. F2The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026.
  3. F325% of the shares subject to the option vested on February 1, 2024, and 1/36th of the remaining shares subject to the option shall vest each month thereafter.
Open on SEC EDGAR
Richard A. HeymanDirector
4Rule 10b5-1 plan disclosed
Filed Jul 28, 2026Period of report Jul 24, 20260001584759-26-000015
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 24, 2026
Common StockF17,000$12.02$84.14K38,300Direct
SaleJul 24, 2026
Common StockF1F26,100$12.02$73.32K206,672IndirectSee footnote
Filing footnotes · 3
  1. F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  2. F2The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
  3. F3The shares subject to the option are fully vested and immediately exercisable.
Open on SEC EDGAR
Richard A. HeymanDirector
4Rule 10b5-1 plan disclosed
Filed Jul 8, 2026Period of report Jul 6, 20260001584759-26-000012
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJul 6, 2026
Common StockF1F2300$12.00$3.60K212,772IndirectSee footnote
Filing footnotes · 2
  1. F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  2. F2The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Open on SEC EDGAR
Dominic PiscitelliChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Feb 26, 2026Period of report Feb 24, 20260001695028-26-000004
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 24, 2026
Common StockF1F252,000$13.5132$702.69K68,148Direct
Filing footnotes · 2
  1. F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2025.
  2. F2Represents the weighted average share price of an aggregate total of 52,000 shares sold in the price range of $13.50 to $13.53 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Richard A. HeymanDirector
4Rule 10b5-1 plan disclosed
Filed Jan 20, 2026Period of report Jan 16, 20260001584759-26-000006
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 16, 2026
Common StockF1F23,500$12.0046$42.02K41,800Direct
SaleJan 16, 2026
Common StockF1F2F33,200$12.0046$38.41K213,072IndirectSee footnote
Filing footnotes · 3
  1. F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
  2. F2Represents the weighted average share price of an aggregate total of 6,700 shares sold in the price range of $12.00 to $12.03 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. F3The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
Open on SEC EDGAR
Dominic PiscitelliChief Financial Officer
4
Filed Dec 17, 2025Period of report Dec 15, 20250001695028-25-000008
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 16, 2025
Common StockF3F410,720$9.0604$97.13K68,148Direct
Filing footnotes · 7
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
  2. F2Includes 1,218 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
  3. F3Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
  4. F4Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0396 to $9.1953 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. F51/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
  6. F61/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
  7. F71/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.
Open on SEC EDGAR
Jacob ChackoDirector · PRESIDENT AND CEO
4
Filed Dec 17, 2025Period of report Dec 15, 20250001608936-25-000014
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 16, 2025
Common StockF2F333,374$9.06$302.37K581,711Direct
Filing footnotes · 6
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
  2. F2Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
  3. F3Represents the weighted average share price of an aggregate total of 33,374 shares sold in the price range of $9.0257 to $9.095 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. F41/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
  5. F51/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
  6. F61/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.
Open on SEC EDGAR
Pratik S MultaniChief Medical Officer
4
Filed Dec 17, 2025Period of report Dec 15, 20250001586894-25-000005
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 16, 2025
Common StockF3F410,720$9.0605$97.13K68,149Direct
Filing footnotes · 7
  1. F1Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.
  2. F2Includes an aggregate of 2,771 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.
  3. F3Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.
  4. F4Represents the weighted average share price of an aggregate total of 10,720 shares sold in the price range of $9.0449 to $9.1451 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  5. F51/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.
  6. F61/3 of the RSUs subject to the award shall vest on each of December 15, 2024, December 15, 2025 and December 15, 2026.
  7. F71/3 of the RSUs subject to the award shall vest on each of December 15, 2025, December 15, 2026 and December 15, 2027.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.